Context Therapeutics (CNTX) Registration Filing summary

Company overview and business model

• Focuses on developing T cell engaging (TCE) bispecific antibodies for solid tumors, with a portfolio including CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3).

• CTIM-76 is entering Phase 1 trials for CLDN6-positive gynecologic and testicular cancers, with first patient dosing expected by end of 2024 and initial data in H1 2026.

• CT-202 was licensed from BioAtla, with an upfront payment of $11M and up to $122.5M in milestones plus royalties; IND filing expected mid-2026.

• CT-95 was acquired from Link Immunotherapeutics for $3.75M and targets advanced cancers with MSLN expression; Phase 1 trial to begin Q1 2025, with data in mid-2026.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be allocated as described in future prospectus supplements, with specific uses to be detailed at the time of each offering.

Risk factors and disclosures

• Investment involves risks, including those detailed in the most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

• Additional risks may arise that are not currently known or deemed material.